SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 34 filers reported holding SEELOS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,605 | -80.9% | 30,457 | +24.0% | 0.00% | – |
| Q2 2023 | $29,346 | +109.6% | 24,557 | +22.4% | 0.00% | – |
| Q1 2023 | $14,000 | – | 20,057 | +35087.7% | 0.00% | – |
| Q4 2022 | $0 | – | 57 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 57 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 57 | -99.9% | 0.00% | – |
| Q1 2022 | $39,000 | -75.3% | 46,129 | -52.7% | 0.00% | – |
| Q4 2021 | $158,000 | +73.6% | 97,449 | +158.1% | 0.00% | – |
| Q3 2021 | $91,000 | +18.2% | 37,761 | +29.7% | 0.00% | – |
| Q2 2021 | $77,000 | – | 29,122 | +181912.5% | 0.00% | – |
| Q1 2021 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 16 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 16 | -51.5% | 0.00% | – |
| Q1 2019 | $0 | – | 33 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |